RxDoctor Payments Data

Aaron Banta

Optometrist · Kennewick, WANPI 1831166891

Payments from drug & device makers

$1,340in general payments, 2019–2025

Across 37 payments — averaging $36.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$401
  • AbbVie$251
  • Oyster Point Pharma, Inc.$151
  • Biotissue Holdings Inc.$124
  • Apellis Pharmaceuticals, Inc.$113
  • Coopervision Inc.$88
  • plus $212 from 6 others

What the payments were for

  • Food & beverage$1,30397%
  • Education$181%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,340 in reported general payments places this provider in the 70th percentile of 1,267 optometrist providers in Washington.

See all optometrist providers in Washington

Medicare billing

Part B allowed, 2024
$135,074
Medicare patients
560
Services billed
1,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$19,277
Alphagan PBrimonidine Tartrate13$7,613
AlrexLoteprednol Etabonate13$3,684
Travoprost15$3,251
Latanoprost146$2,574
Brimonidine Tartrate17$1,547
Prednisolone Acetate33$1,542
Ketorolac Tromethamine13$751
Timolol Maleate47$687
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$607
Dorzolamide Hcl16$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P$251$26,88931 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex$19$3,68413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,267 optometrist providers in Washington.

Other optometrist in Kennewick

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →